Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of MenB and PCV13
NCT02482636Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Aug 2015
- Primary completion
- Nov 2017
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pneumococcal 13-valent conjugate vaccine in invasive pneumococcal disease (IPD), sponsored by University of Oxford. Started Aug 2015; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT02482636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482636.